Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
8.15
0.00 (0.00%)
May 16, 2025, 10:32 AM - Market open
Aurinia Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Aurinia Pharmaceuticals stock ranges from a low of $10 to a high of $13. The average analyst price target of $11.5 forecasts a 41.10% increase in the stock price over the next year.
Price Target: $11.50 (+41.10%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 16, 2024.
Analyst Ratings
The average analyst rating for Aurinia Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $10 | Buy | Reiterates | $10 | +22.70% | Sep 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $10 | Buy | Reiterates | $10 | +22.70% | Sep 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +59.51% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +59.51% | Mar 1, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $12 → $10 | Buy | Maintains | $12 → $10 | +22.70% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
263.03M
from 235.13M
Increased by 11.86%
Revenue Next Year
328.68M
from 263.03M
Increased by 24.96%
EPS This Year
0.45
from 0.04
Increased by 1,037.30%
EPS Next Year
0.77
from 0.45
Increased by 68.16%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 273.0M | 459.6M | 556.4M | ||
| Avg | 263.0M | 328.7M | 400.2M | ||
| Low | 250.7M | 284.2M | 313.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.1% | 74.7% | 69.3% | ||
| Avg | 11.9% | 25.0% | 21.7% | ||
| Low | 6.6% | 8.0% | -4.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.61 | 1.40 | 1.82 | ||
| Avg | 0.45 | 0.77 | 1.12 | ||
| Low | 0.33 | 0.44 | 0.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,422.5% | 207.0% | 137.5% | ||
| Avg | 1,037.3% | 68.2% | 46.2% | ||
| Low | 733.0% | -3.1% | -10.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.